Tenet Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw strong revenue and margin growth, with adjusted EBITDA up 16.3% year-over-year and EPS up 52%. Guidance for 2026 was raised across revenue, EBITDA, and free cash flow, supported by high-acuity strategies, disciplined expense management, and robust capital deployment.
-
Q1 volumes improved sequentially, supporting a strong outlook and confidence in annual guidance. Growth strategies focus on high acuity services, ambulatory expansion, and operational efficiency through AI. Capital deployment prioritizes M&A and share repurchases, with a strong cash position maintained.
-
Q1 2026 saw revenues of $5.4B and adjusted EBITDA of $1.16B, both above expectations, driven by strong cost management and high-acuity growth. Guidance for 2026 is reaffirmed, with robust cash flow and continued capital deployment for M&A and share repurchases.
-
Strong demand for high-acuity care and disciplined capital deployment support robust growth projections. AI and automation drive efficiency, while commercial rates remain favorable and ambulatory expansion continues. Capital priorities include service line investment, share buybacks, and debt reduction.
-
An accretive $2.65 billion asset sale of Conifer's contract with CommonSpirit strengthens cash flow, returns full strategic control, and enables accelerated investment in automation, AI, and offshoring. Capital allocation priorities remain focused on share repurchases and USPI growth.
Fiscal Year 2025
-
2025 saw strong revenue and margin growth, with Adjusted EBITDA up 14% and robust free cash flow. 2026 guidance anticipates continued growth, though headwinds from expiring tax credits are expected. Capital deployment remains focused on M&A, share repurchases, and technology-driven efficiencies.
-
Q3 2025 saw strong revenue and EBITDA growth, margin expansion, and robust free cash flow, prompting raised full-year guidance for revenue, EBITDA, and capital expenditures. USPI and hospital segments both delivered solid performance, with continued M&A activity and disciplined cost controls supporting future growth.
-
Earnings and free cash flow guidance were raised, driven by strong core performance and margin expansion. Policy focus is on extending premium tax credits and Medicaid payments, while capital investment is increasing in high-acuity and ambulatory growth. Operational efficiency and cost control remain priorities.
-
Q2 2025 saw 19% adjusted EBITDA growth and margin expansion, with strong USPI and hospital performance. Full-year guidance was raised for revenue, EBITDA, and free cash flow, supported by high-acuity strategies and robust payer mix.
-
Strong growth in high-acuity ambulatory procedures and disciplined capital deployment are driving revenue and margin improvements. Policy uncertainty is managed through long-term payer contracts and operational focus, while labor and competition remain stable.
-
Q1 2025 saw 14% year-over-year EBITDA growth, margin expansion, and strong cash flow, driven by high patient acuity, favorable payer mix, and disciplined cost management. Guidance for 2025 is reaffirmed, with continued focus on M&A, capital investments, and share repurchases.
-
Medicaid and ACA reforms remain politically sensitive, with strong public support for maintaining coverage. USPI’s growth is driven by high-acuity procedures and disciplined capital deployment, while hospital divestitures and labor management support margin improvement.
Fiscal Year 2024
-
2024 saw robust revenue and EBITDA growth, margin expansion, and significant portfolio transformation through hospital divestitures and ASC additions. 2025 guidance projects continued growth, strong cash flow, and disciplined capital allocation, with regulatory and policy risks closely monitored.
-
Multi-year operational improvements and strategic divestitures have strengthened margins, reduced leverage, and positioned the business for growth. Strong demand, especially in ambulatory surgery, and disciplined capital allocation support a positive outlook into 2025.
-
Q3 2024 results surpassed expectations with strong revenue and EBITDA growth, driven by robust demand, favorable payer mix, and operational discipline. Guidance for full-year adjusted EBITDA was raised, reflecting continued outperformance and portfolio transformation, while free cash flow and leverage metrics improved significantly.
-
The organization has achieved significant deleveraging and portfolio optimization, enabling increased investment in high-growth areas like ambulatory services and acute care hospitals. Strong operational discipline, robust demand, and strategic ASC expansion underpin positive financial outlooks, while exchange and Medicaid dynamics remain key focus areas.
-
Q2 2024 results surpassed expectations with 12% Adjusted EBITDA growth and strong performance in both USPI and hospital segments. Full-year guidance was raised for revenue, EBITDA, and free cash flow, supported by robust demand, cost control, and strategic capital deployment.